CNTA
Centessa Pharmaceuticals
CNTA
CNTA
49 hedge funds and large institutions have $470M invested in Centessa Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
8% more capital invested
Capital invested by funds: $435M → $470M (+$34.2M)
0.95% more ownership
Funds ownership: 73.57% → 74.52% (+0.95%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
49
Holding in Top 10
3
Calls
$166K
Puts
$14K
Top Buyers
| 1 | +$13.2M | |
| 2 | +$3.76M | |
| 3 | +$2.09M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.2M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.07M |
Top Sellers
| 1 | -$3.11M | |
| 2 | -$3.09M | |
| 3 | -$2.07M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.11M |
| 5 |
SCM
Sio Capital Management
New York
|
-$778K |